Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

SABS

SAB Biotherapeutics Inc

Mar 23 • 04:00PM ET

3.93

+0.18 4.80 %

Healthcare • Biotechnology • USA • NASD

Peers: GILD ONC IONS FATE ALLO AFMD TGTX NKTR KOD PBYI

| Held by: VTI SURI VXF AVSC

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-2.67	Insider Own	27.74%	Shs Outstand	47.61M	Perf Week	-0.25%
Market Cap	200.24M	Forward P/E	-	EPS next Y	-0.45	Insider Trans	0.00%	Shs Float	36.82M	Perf Month	10.08%
Enterprise Value	109.60M	PEG	-	EPS next Q	-0.21	Inst Own	55.65%	Short Float	4.38%	Perf Quarter	-0.51%
Income	-12.82M	P/S	-	EPS this Y	8.12%	Inst Trans	14.88%	Short Ratio	3.15	Perf Half Y	59.11%
Sales	0.00M	P/B	1.24	EPS next Y	37.62%	ROA	-11.62%	Short Interest	1.61M	Perf YTD	5.08%
Book/sh	3.18	P/C	2.07	EPS next 5Y	15.91%	ROE	-14.45%	52W High	6.60 -40.45%	Perf Year	128.49%
Cash/sh	1.90	P/FCF	-	EPS past 3/5Y	43.07% -	ROIC	-8.19%	52W Low	1.00 293.00%	Perf 3Y	-21.40%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	5.90% 8.13%	Perf 5Y	-95.99%
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	67.23%	Oper. Margin	-	ATR (14)	0.33	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	9.46	Sales Y/Y TTM	-100.00%	Profit Margin	-	RSI (14)	48.77	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	9.46	EPS Q/Q	33.75%	SMA20	-1.53%	Beta	0.62	Target Price	10.00
Payout	-	Debt/Eq	0.04	Sales Q/Q	-100.00%	SMA50	-2.38%	Rel Volume	1.03	Prev Close	3.75
Employees	86	LT Debt/Eq	0.03	Earnings	Mar 09 AMC	SMA200	29.72%	Avg Volume	511.76K	Price	3.93
IPO	Feb 09, 2021	Option/Short	Yes / Yes	EPS/Sales Surpr.	-2.95% -	Trades		Volume	525,573	Change	4.80%

Date	Action	Analyst	Rating Change	Price Target Change
Dec-19-25	Initiated	Guggenheim	Buy	$15
Sep-17-25	Initiated	Leerink Partners	Outperform	$7
May-14-25	Resumed	H.C. Wainwright	Buy	$10
Oct-09-24	Initiated	Craig Hallum	Buy	$11
Aug-28-24	Initiated	Oppenheimer	Outperform	$12
Nov-05-21	Initiated	Chardan Capital Markets	Buy	$17

Mar-19-26 04:01PM	SAB BIO Announces Closing of $85 Million Public Offering of Common Stock and Pre-Funded Warrants (GlobeNewswire)
Mar-17-26 10:46PM	SAB BIO Announces Pricing of $85 Million Public Offering of Common Stock and Pre-Funded Warrants (GlobeNewswire) -9.09%
04:01PM	SAB BIO Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants (GlobeNewswire)
Mar-10-26 07:31AM	SAB BIO Announces Additional Phase 1 Data for SAB-142 in Adult Patients with Established Autoimmune Type 1 Diabetes (GlobeNewswire) +6.77%
Mar-09-26 05:16PM	SAB BIO Reports Full Year 2025 Financial Results and Business Highlights (GlobeNewswire)
09:00AM	Loading…
Mar-02-26 09:00AM	SAB BIO to Participate in Upcoming Investor Conferences (GlobeNewswire)
Mar-01-26 02:43PM	SAB Biotherapeutics Pitches SAB-142 as Redosable Human ATG for Type 1 Diabetes at Oppenheimer Conf (MarketBeat)
Feb-15-26 01:05AM	SAB Biotherapeutics Spotlights SAB-142 Phase 2b Plan in Type 1 Diabetes at Guggenheim Summit 2026 (MarketBeat)
Feb-04-26 09:00AM	SAB BIO to Participate in Upcoming Investor Conferences (GlobeNewswire)
Jan-25-26 06:05AM	Analysts Predict Up to 400% Spike for These 2 Strong Buy Penny Stocks (TipRanks)
Jan-07-26 08:00AM	SAB BIO Strengthens Board of Directors with Appointment of New Chair and New Director (GlobeNewswire) +9.67%
Jan-06-26 08:00AM	SAB BIO to Present at the 44th Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-18-25 08:00AM	First Patient Dosed in SAB BIO's SAFEGUARD Clinical Trial of SAB-142 for the Treatment of Stage 3 T1D (GlobeNewswire)
Dec-17-25 08:00AM	SAB BIO Announces Positive Confirmatory Clinical Results from the Phase 1 Study of SAB-142 in Development for the Treatment of Stage 3 T1D (GlobeNewswire)
Dec-08-25 08:00AM	SAB BIO to Present Data Showcasing Progress in the Development of SAB-142 at the Asian Conference on Innovative Therapies for Diabetes Management (GlobeNewswire) -10.80%
05:00PM	Loading…
Nov-13-25 05:00PM	SAB BIO Reports Third Quarter Financial Results and Recent Business Highlights (GlobeNewswire) -9.09%
Nov-04-25 08:30AM	SAB BIO to Present Data at the International Society for Pediatric and Adolescent Diabetes Annual Conference Showcasing Progress in the Development of SAB-142 (GlobeNewswire)
08:00AM	SAB BIO to Participate in Upcoming Investor Conferences (GlobeNewswire)
Sep-19-25 07:24AM	SAB BIO Highlights Data in Multiple Presentations at EASD (GlobeNewswire) -11.47%
Sep-03-25 04:05PM	SAB BIO to Deliver Five Presentations Related to SAB-142 at the 2025 Annual Meeting of the European Association for the Study of Diabetes (GlobeNewswire) +9.43%
Aug-07-25 10:00AM	SAB Biotherapeutics, Inc. (SABS) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release (Zacks)
07:30AM	SAB BIO Reports Second Quarter Financial Results and Highlights Company Updates (GlobeNewswire)
Jul-21-25 10:30AM	BC-Most Active Stocks (Associated Press Finance) +5.06%
07:30AM	SAB BIO Announces Oversubscribed $175 Million Private Placement (GlobeNewswire)
May-09-25 09:00AM	SAB BIO Announces Q1 2025 Financial Results and Provides Company Updates (GlobeNewswire)
May-08-25 06:10PM	Oculis Holding AG (OCS) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
May-06-25 05:10PM	Arcutis Biotherapeutics, Inc. (ARQT) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
Mar-31-25 07:32AM	SAB BIO Reports Full Year 2024 Operating and Financial Results (GlobeNewswire) -8.11%
Jan-31-25 07:00AM	SAB BIO to Participate in Upcoming Investor Conferences (GlobeNewswire)
Jan-28-25 07:00AM	SAB BIO Announces Positive Topline Phase 1 Clinical Results with Potentially Disease-Modifying T1D Therapy SAB-142 (GlobeNewswire) -52.52%
07:00AM	Loading…
Jan-23-25 07:00AM	SAB BIO Announces R&D Webinar Event to Review Phase 1 Topline Results for SAB-142, a Disease-Modifying T1D Therapy (GlobeNewswire)
Nov-15-24 09:50AM	These 2 Strong Buy Penny Stocks Are Set to Triple (or more), Say Analysts (TipRanks) -16.22%
Nov-06-24 05:05PM	SAB BIO Announces Third Quarter 2024 Financial Results and Provides Company Update (GlobeNewswire) -17.22%
Oct-31-24 07:00AM	SAB BIO CEO to Participate in Fireside Chat at Guggenheim Securities Healthcare Innovation Conference (GlobeNewswire)
Sep-13-24 07:00AM	SAB BIO CEO to Participate in Fireside Chat at 2024 Cantor Global Healthcare Conference (GlobeNewswire)
Sep-09-24 07:00AM	SAB BIO Provides SAB-142 Clinical Trial Progress Update at the European Association for the Study of Diabetes Annual Meeting (GlobeNewswire)
Sep-04-24 07:05AM	SAB BIO to Present at the European Association for the Study of Diabetes 60th Annual Meeting (GlobeNewswire)
Aug-08-24 05:51PM	SAB BIO Announces Second Quarter 2024 Financial Results and Provides Company Updates (GlobeNewswire) -12.91%
Aug-05-24 07:30AM	SAB BIO Announces Founding of Clinical Advisory Board to Guide the Development of SAB-142 for Type 1 Diabetes (GlobeNewswire)
Jul-31-24 07:30AM	SAB BIO Appoints Lucy To as Chief Financial Officer (GlobeNewswire)
Jun-20-24 07:20AM	SAb Biotherapeutics Rebrands as SAB BIO (GlobeNewswire) +7.36%
Jun-18-24 01:10PM	SAB Biotherapeutics to Present at the American Diabetes Association 84th Scientific Sessions (GlobeNewswire) -20.62%
May-30-24 04:45PM	SAB Biotherapeutics Announces Departure of Chief Financial Officer (GlobeNewswire) -6.38%
May-21-24 09:53AM	SABS Stock Earnings: SAB Biotherapeutics Misses EPS for Q1 2024 (InvestorPlace) -15.65%
07:15AM	FDA Provides Clearance to IND Application for Type 1 Diabetes Therapy SAB-142 by SAB Biotherapeutics (GlobeNewswire)
May-20-24 05:45PM	SAB Biotherapeutics Announces Q1 2024 Financial Results and Provides Company Updates (GlobeNewswire)
May-06-24 07:15AM	SAB Biotherapeutics Appoints Jay Skyler, MD, to the Board of Directors (GlobeNewswire)
Apr-16-24 07:15AM	SAB Biotherapeutics Provides SAB-142 Trial Update (GlobeNewswire) +5.86%
Apr-08-24 07:15AM	SAB Biotherapeutics to Present at INNODIA Annual Meeting (GlobeNewswire)
Apr-04-24 07:15AM	SAB Biotherapeutics to Present at the Needham Virtual Healthcare Conference (GlobeNewswire)
Mar-29-24 07:15AM	SAB Biotherapeutics Reports Full Year 2023 Operating and Financial Results (GlobeNewswire)
Mar-25-24 10:15AM	SAB Biotherapeutics Announces Clinical Partnership with Naval Medical Research Center to Advance Potential Influenza Treatment (GlobeNewswire) -12.91%
Feb-23-24 08:00AM	SAB Biotherapeutics to Present at the BIO CEO & Investor Conference (GlobeNewswire)
Feb-08-24 08:00AM	SAB Biotherapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference (GlobeNewswire)
Feb-02-24 07:30AM	SAB Biotherapeutics Announces Executive Leadership Change (GlobeNewswire)
Jan-23-24 05:58PM	SAB Biotherapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement (GlobeNewswire)
Jan-02-24 04:30PM	SAB Biotherapeutics Announces 1-for-10 Reverse Stock Split (GlobeNewswire)
Nov-29-23 01:29PM	SAB Biotherapeutics Starts Human Clinical Trial of Diabetes Treatment (Exec Edge) -5.43%
07:30AM	SAB Biotherapeutics Announces Commencement of the HUMAN Phase 1 Clinical Trial with SAB-142, a Potential Disease-Modifying Treatment for Type 1 Diabetes (GlobeNewswire)
Nov-20-23 07:30AM	SAB Biotherapeutics Appoints Katie Ellias to the Board of Directors (GlobeNewswire)
Nov-14-23 01:35PM	SAB Biotherapeutics 3Q Loss Narrows, Completes $67.1M in Financing (Exec Edge)
07:30AM	SAB Biotherapeutics Announces Completion of $67.1 Million Financing to Advance Potential Disease-Modifying Treatment for Type 1 Diabetes (GlobeNewswire)
07:15AM	SAB Biotherapeutics Announces Q3 2023 Financial Results and Provides Company Updates (GlobeNewswire)
Nov-09-23 07:30AM	SAB Biotherapeutics to Present at Piper Sandler Healthcare Conference (GlobeNewswire)
Oct-24-23 07:30AM	SAB Biotherapeutics Appoints Michael G. King Jr. as Chief Financial Officer (GlobeNewswire)
Oct-19-23 07:30AM	SAB Biotherapeutics Receives Australian Approval to Commence Phase 1 Clinical Trial of SAB-142, a Potential Disease-Modifying Treatment for Type 1 Diabetes (GlobeNewswire) +28.53%
Oct-05-23 07:30AM	SAB Biotherapeutics Approves Appointment of Andrew Moin to Board of Directors (GlobeNewswire)
Oct-03-23 11:31AM	SAB Biotherapeutics Will Sell $130 Million Shares of Preferred Stock to Advance Diabetes Treatment (Exec Edge)
Oct-02-23 07:30AM	SAB Biotherapeutics Announces Private Placement of up to $130 Million to Advance Development of Lead Drug Candidate for Type 1 Diabetes (GlobeNewswire)
Aug-21-23 08:30AM	SAB Biotherapeutics Provides Company Update for Q2 2023 Financial Results (GlobeNewswire)
Jul-12-23 11:04AM	Swiss Franc Jumps to Highest Against Dollar Since SNB Lifted Cap (Bloomberg)
Jun-21-23 08:30AM	SAB Biotherapeutics Presents Positive IND-Enabling GLP Toxicology Study for SAB-142, a Novel Immunotherapeutic for Type 1 Diabetes at FOCIS 2023 (GlobeNewswire)
May-30-23 08:30AM	SAB Biotherapeutics to Present Novel Human IgG Platform with Positive Data and Breakthrough Therapy and Fast-Track Designations for Influenza Treatment at BIO 2023 International Convention (GlobeNewswire)
May-19-23 08:30AM	SAB Biotherapeutics Presents Virtual 2023 R&D Day Portfolio Update: Breakthrough Immunotherapy Innovations (GlobeNewswire)
May-16-23 08:30AM	SAB Biotherapeutics Provides Company Update for Q1 2023 Financial Results (GlobeNewswire) -11.36%
May-12-23 08:30AM	SAB Biotherapeutics Announces First Publication of Promising Nonclinical Data for SAB-183 Against Pneumonic Plague in the Journal Antibodies (GlobeNewswire)
May-09-23 08:30AM	SAB Biotherapeutics Announces Progress on U.S. FDAs Phased Review of Companys Groundbreaking DiversitAb Platform (GlobeNewswire) -6.22%
07:15AM	Sidoti's Micro-Cap Virtual May Conference (ACCESSWIRE)
May-04-23 08:30AM	SAB Biotherapeutics Presents Positive Phase 1 and 2a Data for SAB-176 Influenza Immunotherapy at ISIRV-AVG Conference (GlobeNewswire)
May-03-23 05:00PM	SAB Biotherapeutics to Present at Sidoti Virtual Investor Conference, May 10-11 (GlobeNewswire)
Apr-26-23 08:30AM	SAB Biotherapeutics Announces Positive Results from Phase 3 Trial of SAB-185 in Patients with COVID-19 at High-Risk for Severe Complications (GlobeNewswire) -6.90%
Apr-18-23 08:30AM	SAB Biotherapeutics Announces U.S. FDA Grants Breakthrough Therapy Designation to SAB-176 Influenza Immunotherapy (GlobeNewswire) +41.56%
Apr-13-23 08:30AM	SAB Biotherapeutics Granted Fast Track Designation from FDA for SAB-176 Influenza Immunotherapy with High Cross-Reactivity to Multiple Strains of Influenza (GlobeNewswire) +99.71%
Apr-04-23 08:00AM	SAB Biotherapeutics Announces Appointment of Erick Lucera, CFA to Board of Directors (GlobeNewswire)
Mar-31-23 05:00PM	SAB Biotherapeutics Provides Company Update for Full Year 2022 (GlobeNewswire) +5.09% +5.68%
Jan-19-23 08:00AM	SAB Biotherapeutics CEO Eddie Sullivan, PhD, to Present Next Generation Biologics in Immunology at BIO CEO & Investor Conference (GlobeNewswire)
Jan-18-23 08:30AM	SAB Biotherapeutics Gets Another $8.2 million from Department of Defense in Closeout Settlement (Exec Edge)
08:00AM	SAB Biotherapeutics Receives an Additional $8.2 Million in Closeout of DoD Contract (GlobeNewswire)
Jan-10-23 08:00AM	SAB Biotherapeutics Successfully Concludes IND-Enabling GLP Toxicology Study for SAB-142, a Novel Immunotherapeutic for Type 1 Diabetes (GlobeNewswire)
Jan-09-23 08:00AM	SAB Biotherapeutics CMO Alexandra Kropotova to Deliver Presentation on Next Generation Biologics in Immunology at Biotech Showcase (GlobeNewswire) +11.46%
Jan-05-23 08:00AM	SAB Biotherapeutics Novel DiversitAb Platform Proven to Develop Anti-idiotype Antibodies to Help Treat Autoimmune Diseases (GlobeNewswire)
Dec-15-22 08:30AM	SAB Biotherapeutics CMO Selected to Present at the January 2023 Biotech Showcase in San Francisco (GlobeNewswire) -6.10%
Dec-11-22 08:20AM	Independent Director Jeffrey Spragens Just Bought 27% More Shares In SAB Biotherapeutics, Inc. (NASDAQ:SABS) (Simply Wall St.)
Dec-07-22 05:16PM	SAB Biotherapeutics Announces $7.9 Million Private Placement of Common Stock (GlobeNewswire) -6.45%
Nov-21-22 08:14AM	SAB Biotherapeutics Initiates IND-Enabling GLP Toxicology Study for SAB-142, Novel Immunotherapeutic for Type 1 Diabetes (GlobeNewswire) -9.17%
Nov-17-22 05:32AM	SAB Biotherapeutics Third Quarter 2022 Earnings: Misses Expectations (Simply Wall St.)
Nov-15-22 08:30AM	SAB Biotherapeutics Provides Company Update for Q3 2022 Financial Results (GlobeNewswire) -15.20%
Nov-08-22 08:30AM	SAB Biotherapeutics Presents Novel Biologic Therapeutics for Infectious Diseases at U.S. Pharma Partnering Summit 2022 (GlobeNewswire) +8.65%
Nov-03-22 09:00AM	SAB Biotherapeutics Presents Overview of DiversitAb Platform and Data Showing Benefits of Fully-Human Polyclonal Antibodies Derived from Cows vs. Human-Derived Plasma, at 2022 Plasma Product Biotechnology Conference (GlobeNewswire)
Oct-27-22 08:30AM	SAB Biotherapeutics Announces Exclusive Manufacturing Partnership with Emergent BioSolutions (GlobeNewswire) +6.33%

SAB Biotherapeutics, Inc. is a clinical-stage, biopharmaceutical company, which engages in advancing a new class of immunotherapies leveraging fully-human polyclonal antibodies. The firm produces human polyclonal immunotherapies and its versatile DiversitAb platform is applicable for unmet needs in human diseases. The company was founded by Eddie J. Sullivan and Christine E. Hamilton in July 2014 and is headquartered in Miami Beach, FL.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Moin Andrew	Director	Sep 29 '25	Option Exercise	1.75	1,740,000	3,045,000	2,198,457	Oct 01 04:35 PM
Sessa Capital (Master), L.P.	Director	Sep 29 '25	Option Exercise	1.75	1,740,000	3,045,000	2,198,457	Oct 01 04:06 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

SABS

SAB Biotherapeutics Inc

Upgrade your FINVIZ experience